BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10884552)

  • 1. Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors.
    Schweitzer C; Kratzeisen C; Adam G; Lundstrom K; Malherbe P; Ohresser S; Stadler H; Wichmann J; Woltering T; Mutel V
    Neuropharmacology; 2000 Jul; 39(10):1700-6. PubMed ID: 10884552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain.
    Schaffhauser H; Richards JG; Cartmell J; Chaboz S; Kemp JA; Klingelschmidt A; Messer J; Stadler H; Woltering T; Mutel V
    Mol Pharmacol; 1998 Feb; 53(2):228-33. PubMed ID: 9463480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells.
    Johnson BG; Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    Neuropharmacology; 1999 Oct; 38(10):1519-29. PubMed ID: 10530814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding.
    Richards G; Messer J; Malherbe P; Pink R; Brockhaus M; Stadler H; Wichmann J; Schaffhauser H; Mutel V
    J Comp Neurol; 2005 Jun; 487(1):15-27. PubMed ID: 15861463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
    Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
    J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes.
    Cartmell J; Adam G; Chaboz S; Henningsen R; Kemp JA; Klingelschmidt A; Metzler V; Monsma F; Schaffhauser H; Wichmann J; Mutel V
    Br J Pharmacol; 1998 Feb; 123(3):497-504. PubMed ID: 9504391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2.
    Doornbos MLJ; Vermond SC; Lavreysen H; Tresadern G; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 Sep; 155():356-365. PubMed ID: 30028996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain.
    Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    J Pharmacol Exp Ther; 2001 Aug; 298(2):453-60. PubMed ID: 11454905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activation of either mGlu2 or mGlu3 receptors can induce LTD in the amygdala.
    Lucas SJ; Bortolotto ZA; Collingridge GL; Lodge D
    Neuropharmacology; 2013 Mar; 66():196-201. PubMed ID: 22531751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors.
    Malherbe P; Richards JG; Broger C; Zenner MT; Messer J; Kratzeisen C; Nakanishi S; Mutel V
    J Neurochem; 2005 Jul; 94(1):150-60. PubMed ID: 15953358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of essential residues involved in the glutamate binding pocket of the group II metabotropic glutamate receptor.
    Malherbe P; Knoflach F; Broger C; Ohresser S; Kratzeisen C; Adam G; Stadler H; Kemp JA; Mutel V
    Mol Pharmacol; 2001 Nov; 60(5):944-54. PubMed ID: 11641422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782.
    Lavreysen H; Langlois X; Ahnaou A; Drinkenburg W; te Riele P; Biesmans I; Van der Linden I; Peeters L; Megens A; Wintmolders C; Cid JM; Trabanco AA; Andrés JI; Dautzenberg FM; Lütjens R; Macdonald G; Atack JR
    J Pharmacol Exp Ther; 2013 Sep; 346(3):514-27. PubMed ID: 23766542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
    Tizzano JP; Griffey KI; Schoepp DD
    Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist.
    Hanna L; Ceolin L; Lucas S; Monn J; Johnson B; Collingridge G; Bortolotto Z; Lodge D
    Neuropharmacology; 2013 Mar; 66():114-21. PubMed ID: 22445601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo.
    Linden AM; Bergeron M; Schoepp DD
    Neuropharmacology; 2005; 49 Suppl 1():120-34. PubMed ID: 16023151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
    Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):546-54. PubMed ID: 11138847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain.
    Felder CC; Schober DA; Tu Y; Quets A; Xiao H; Watt M; Siuda E; Nisenbaum E; Xiang C; Heinz B; Prieto L; McKinzie DL; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):190-197. PubMed ID: 28138041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.